Case Study: Recurrence of Felty Syndrome Triggered by Immunotherapy in a Metastatic Melanoma Patient

1

Immune checkpoint inhibitors can trigger immune-related adverse events, particularly in patients with pre-existing autoimmune conditions.
2

A 71-year-old man with metastatic melanoma experienced a recurrence of Felty syndrome after receiving nivolumab and relatlimab immunotherapy.
3

The patient presented with neutropenia (ANC 0.0 cells/µL) but showed no active synovitis, complicating the diagnosis.
4

Management included intravenous methylprednisolone and methotrexate, leading to rapid recovery of neutrophil counts.
5

Early identification of ICI-induced Felty syndrome is crucial to prevent severe complications like neutropenia in vulnerable patients.

1